Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH. · 2008

Read Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. by Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2440807.txt.

Introduction

Chen and colleagues studied stem-like lung cancer cells and a gene that keeps them potent in 2008. They split cells from ten patients' non-small-cell lung tumors, and five cell lines, by the surface marker CD133. The CD133-positive cells expressed high levels of Oct-4, a gene that maintains stem cell identity.

These positive cells renewed themselves and acted as a reservoir able to generate the full tumor cell mix. They also carried the drug-resistance marker ABCG2 and withstood four chemotherapy drugs and radiation far better than negative cells. Silencing Oct-4 with a small RNA tool stripped their powers: sphere growth stopped, invasion and colony formation fell, and cell death signals rose. Tumors from these cells also responded better to combined chemo-radiation once Oct-4 was silenced. The authors cast Oct-4 as the linchpin of the stem-like state.

Catalog record

CREATORChen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2440807

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells By Yu-Chih Chen, Han-Shui Hsu, Yi-Wei Chen, Tung-Hu Tsai, Chorng-Kuang How, Chien-Ying Wang, Shih-Chieh Hung, Yuh-Lih Chang, Ming-Long Tsai, Yi-Yen Lee, Hung-Hai Ku, Shih-Hwa Chiou Published in: PLoS ONE DOI: 10.1371/journal.pone.0002637 ABSTRACT Abstract CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered to be an important marker that represents the subset population of cancer stem-like cells. Herein we report the isolation of CD133-positive cells (LC-CD133+) and CD133-negative cells (LC-CD133−) from tissue samples of ten patients with non-small cell lung cancer (LC) and five LC cell lines. LC-CD133+ displayed higher Oct-4 expressions with the ability to self-renew and may represent a reservoir with proliferative potential for generating lung cancer cells. Furthermore, LC-CD133+, unlike LC-CD133−, highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy. The treatment of Oct-4 siRNA with lentiviral vector can specifically block the capability of LC-CD133+ to form spheres and can further facilitate LC-CD133+ to differentiate into LC-CD133−. In addition, knock-down of Oct-4 expression in LC-CD133+ can significantly inhibit the abilities of tumor invasion and colony formation, and increase apoptotic activities of caspase 3 and poly (ADP-ribose) polymerase (PARP). Finally, in vitro and in vivo studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133+ can be improved by the treatment of Oct-4 siRNA. In conclusion, we demonstrated that Oct-4 expression plays a crucial role in maintaining the self-renewing, cancer stem-like, and chemoradioresistant properties of LC-CD133+. Future research is warranted regarding the up-regulated expression of Oct-4 in LC-CD133+ and malignant lung cancer. INTRODUCTION Lung cancer is one of the leading causes of cancer-related deaths in industrialized countries [1], [2]. Radiotherapy and chemotherapy play significant and crucial roles in clinical anti-lung cancer treatment to achieve prolonged patient survival [3], [4]. However, a high failure rate and low median survival rate are observed in patients undergoing chemoradiotherapy with recurrent, intractable lung cancer [5]. To improve the patient survival rate, investigation to elucidate the mechanism of tumorigenesis of lung cancer is needed [5]. Recent data have demonstrated that tumors contain a small subpopulation of cells, i.e., cancer stem-like cells (CSCs) or cancer-initiating cells (CICs), which exhibit a self-renewing capacity and are responsible for tumor maintenance and metastasis [6]. Stem cells have been isolated by their ability to efflux Hoechst 33342 dye and are referred to as the “side population (SP)” [7]. Ho and colleagues isolated and characterized SP cells from six human lung cancer cell lines and showed that an elevated expression of ABCG2 as well as other ATP-binding cassette transporters were positively correlated with resistance to multiple chemotherapeutic drugs [8]. In addition, Gutova and colleagues have purified uPAR-positive CSCs from three lung cancer cell lines. These uPAR-positive cells co-expressed with CD44 and MDR1, and had the ability to promote advanced malignancy and chemoresistance [9]. CD133 (prominin-1), a 5-transmembrane glycoprotein, was first recognized in CD34+ progenitor populations from adult blood, bone marrow, and fetal liver cells [10]. Recently, CD133 has been considered an important marker to represent the subset population of CSCs in leukemia, brain tumors, retinoblastoma, renal tumors, pancreatic tumors, colon carcinoma, prostate carcinoma, and hepatocellular carcinoma [11]–[19]. Based on immunohistochemical findings, Hilbe and colleagues suggested that CD133-positive (CD133+) progenitor cells play a role in the development of tumor vasculature in patients with non-small-cell lung cancer (NSCLC) [20]. More recently, a well-designed study by Eramo and colleagues showed that lung cancer contains a population of CD133+ CSCs able to self-renew and generate an unlimited progeny of non-tumorigenic cells. These CD133+ cells are also resistant to conventional chemotherapy [21]. However, the gene regulation mechanisms in maintaining the self-renewal and drug-resistant properties in putative cancer stem-like cells of lung tumors are still unclear. Oct-4, a member of the family of POU-domain transcription factors, is expressed in pluripotent embryonic stem (ES) and germ cells [22]–[23]. Oct-4 mRNA is normally found in totipotent and pluripotent stem cells of pregastrulation embryos [24]. Knocking out the Oct-4 gene in mice causes early lethality due to the lack of ICM formation, indicating that Oct-4 has a critical function for self-renewal of ES cells [25]. Oct-4 activates transcription via octamer motifs, and Oct-4 binding sites have been found in various genes, including fgf 4 (fibroblast growth factor 4) and pdgfαr (platelet-derived growth factor α receptor) [26], [27]. This suggests that Oct-4 functions as a master switch during differentiation by regulating the pluripotent potentials of the stem cell, and Oct-4 plays a pivotal role in mammalian development [24], [25]. In this study, the CD133-positive cells (LC-CD133+) and CD133-negative cells (LC-CD133−) were isolated from tissue samples of lung cancer (LC) patients and LC cell lines. These LC-CD133+ cells possessed both the characteristics of stem-like cells and malignant tumors. Our data further demonstrated that Oct-4 expression in LC-CD133+ is involved in tumor malignancy of lung cancers and exhibits refractory properties for chemoradiotherapy in cancer stem-like cells. These results suggested that the expression of Oct-4 plays a crucial role in maintaining cancer stem-like and chemoradioresistant properties in lung cancer-derived CD133+ cells. MATERIALS AND METHODS Isolation of CD133+ Cell Subset This research followed the tenets of the Declaration of Helsinki and all samples were obtained after patients provided informed consent. The study was approved by the Institutional Ethics Committee/Institutional Review Board of Taipei Veterans General Hospital. The dissociated cells from the samples of non-small cell lung cancer patients (Table 1) and the lung cancer (LC) cell lines were labeled with 1 mL CD133/l micromagnetic beads per 1 million cells using the CD133 cell isolation kit (Miltenyi Biotech, Auburn, CA). CD133+ cells were cultured in a medium consisting of serum-free DMEM/F12 (Gibco-BRL, Gaithersburg, MD), N2 supplement (R&D Systems Inc., Minneapolis), 10 ng/ml human recombinant bFGF (R&D Systems) and 10 ng/ml EGF (R&D Systems) [28]. [Table: The tumor formation abilities of CD133+ and CD133− in NSCLC description and tumorigenic characteristics of CD133+] Cell Viability Determined by Colorimetric Assay The isolated CD133+ and CD133− cells were cultured in a 96-well cell culture cluster (Corning Costar, Acton, MA) at a density of 3×103 cells/well with 100 µl culture medium. At specific time points during cultivation, the medium was discarded and replaced with an equal volume (100 µl) of fresh medium containing 0.2 mg/ml of 3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, Promega, Madison, WI) and 0.038 mg/ml of phenazine methosulfate (PMS; Promega) and incubated for additional 1.5 hours in 37°C 5% CO2. Cell viability proportionate to optical density (OD) was measured by colorimetric assay in terms of mitochondria activity to convert tetrazolium salt into a colored soluble formazan product in the medium. The OD values were measured at the wavelength of 490 nm with a 1420 multilabel counter VICTOR from Wallac (PerkinElmer Wallac, Turku, Finland). Real-time Reverse Transcription-polymerase Chain Reaction (RT-PCR) For real-time RT-PCR analysis, the total RNA of cells was extracted by using the RNAeasy kit (Qiagen, Valencia, CA). Briefly, the total RNA (1 µg) of each sample was reversely transcribed in 20 µL using 0.5 µg of oligo dT and 200 U Superscript II RT (Invitrogen, Carlsbad, CA). The amplification was carried out in a total volume of 20 µl containing 0.5 µM of each primer, 4 mM MgCl2, 2 µl LightCycler FastStart DNA Master

Read the complete text